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Purpose:  Vascular  endothelial  growth  factor  (VEGF)  plays  a  key  role  in  neovascularization  by  stimulating  the
proliferation and migration of vascular endothelial cells. The anti-VEGF therapy bevacizumab acts by binding to VEGF
and preventing its effects. However, this linear interaction represents only a partial view of the pathobiology of neovascular
diseases and the anti-VEGF treatment. To obtain an integrated view of the processes involved in VEGF-related ocular
pathologies, we applied a systems approach and investigated whether intravitreal bevacizumab injections have a global
effect in normalizing the ocular physiology perturbed by the disease.
Methods: We analyzed 90 analytes representing various pathophysiological processes in aqueous humor. The samples
were  obtained  from  eight  patients  receiving  intravitreal  bevacizumab  injections  for  various  ocular  VEGF-related
conditions. The samples were obtained before and after the injection and were analyzed using microbead technology
developed by Luminex xMAP.
Results: Forty-three analytes were detected above the sensitivity of the assay both in pre- and post-injection samples. Of
these, normal values of 41 analytes were known and these analytes were further analyzed. The detected analytes included
relevant markers such as VEGF, C reactive protein, glutathione, and cytokines. We identified 24 markers that were
perturbed more than 1.5 fold in diseased samples (pre-injection) compared to normal levels. The levels of perturbed
analytes were compared in post-treatment samples. The results demonstrated an unequivocal trend toward normalization
in post-treatment samples.
Conclusions: Our results show intraocular bevacizumab injections change the perturbed physiologic environment of the
eye toward normalization. Its effects reached beyond neutralizing VEGF. The results also demonstrate that large-scale
analysis  of  the  aqueous,  using  a  systems  approach,  could  provide  useful  insight  regarding  ocular  diseases,  their
pathophysiologies, and treatment responses.
Neovascularization,  a  common  pathology  in  several
diseases, results from complex interactions between pro and
antiangiogenic cytokines involving multiple pathways. Of the
various cytokine families that play roles in the development,
maintenance,  and  remodeling  of  microcirculation,  the
vascular endothelial growth factor (VEGF) family is the most
complex and most studied. Vascular endothelial growth factor
stimulates the cell proliferation, migration, and survival of
vascular  endothelial  cells  [1,2].  Anti-VEGF  therapy  has
become  a  widely  accepted  treatment  for  several  diseases
where neovascularization and permeability plays a pivotal
role,  including  cancer  and  retinal  disorders.  Anti-VEGF
therapy, including bevacizumab, acts by binding to VEGF and
preventing its cellular effects. However, this linear interaction
represents  only  a  partial  view  of  the  pathobiology  of  the
disease and treatment processes. Consequently, the classical
concept of linear interactions is being replaced by the concept
of networks of interactions, emphasizing the importance of
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interactions  between  different  components  of  a  biologic
system [3]. With a large number of interacting components in
the process of neovascularization, focus on a single or a small
number of molecules imposes the risk making incomplete and
flawed interpretations. For such a complex process, a systems
biology approach can provide useful insights.
Beyond  genetic  and  environmental  determinants,
diseases  are  characterized  by  a  perturbed  physiology.
Therefore,  methods  providing  deeper  insights  into
physiologic states are essential in acquiring an integrated view
of human disease [4]. Spectacular progresses in quantitative
techniques,  large-scale  measurement  methods,  and
integration  between  experimental  and  computational
approaches has made it possible to understand organisms,
their  physiology,  and  pathobiology  at  the  system  level.
Applications  of  such  system-wide  approaches  to  human
biology, ushered in by the human genome project, are likely
to open new opportunities in medicine.
We have previously demonstrated that using a microbead
assay, a quantitative analysis of a large number of analytes in
aqueous humor can provide useful system-wide information
about the pathophysiological intraocular environment [5]. We
can simultaneously monitor concurrent activities of multiple
molecules  using  this  approach,  enabling  a  broader  and
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2175unbiased view of biologic events. In the current study, we
applied the same methodologies to investigate how VEGF-
related diseases of the eye change the intraocular environment
and whether anti-VEGF therapy has a system-wide effect on
normalizing the perturbed ocular environment.
METHODS
Samples: Aqueous humor was obtained from eight patients
undergoing bevacizumab injections for various VEGF-related
ocular pathologies. Of the eight patients, three were male and
five were female. Two patients were treated for central retinal
vein occlusion (CRVO), one for branch retinal vein occlusion
(BRVO),  two  for  clinically  significant  macular  edema
(CSME),  and  three  for  age-related  macular  degeneration
(AMD).  The  samples  were  drawn  sequentially  on  two
different occasions from the same patient. The first sample
(pre-treatment  sample)  was  drawn  just  before  the  first
intravitreal bevacizumab injection (0.125 mg), representing
the pathological sample. The second sample (post-treatment
sample) was drawn before the second intravitreal injection of
bevacizumab,  representing  the  effect  of  treatment  on  the
aqueous profile after the eye was injected with 0.25 mg of
bevacizumab. Aqueous humor (80–100 µl) was withdrawn
through a limbal paracentesis site using a 27-gauge needle in
a  tuberculin  syringe.  Care  was  taken  to  avoid  touching
intraocular tissues and to prevent contamination of aqueous
samples with blood. The samples were immediately frozen
and stored at −80 °C. Patients with other ocular or systemic
disease, such as inflammatory diseases, were excluded from
the study.
Informed consent was obtained from the patients, and the
research was in compliance with the tenets of the University
of Florida and the Declaration of Helsinki for experiments
involving human tissue.
Multiplex  analysis:  Multiplex  analysis  was  performed  at
Rules-Based  Medicine  (Austin,  TX),  which  uses  multi-
analyte profiles (MAPs) based on powerful Luminex xMAP®
(Luminex Corporation, Austin TX) technology to discover
biomarker patterns within very small sample volumes. The
aqueous samples were thawed at room temperature, vortexed,
and spun at 13,000× g for 5 min to remove any precipitates.
The maximum available volume (80–100 ul) was removed for
MAP antigen analysis into a master microtiter plate. Using
automated pipetting, an aliquot of each sample was introduced
into one of the capture microsphere multiplexes of the human
antigen  MAP.  These  mixtures  of  sample  and  capture
microspheres were thoroughly mixed and incubated at room
temperature for 1 h. Multiplexed cocktails of biotinylated
reporter  antibodies  for  each  multiplex  were  then  added
robotically and were thoroughly mixed. The mixture was then
incubated  for  an  additional  1  h  at  room  temperature.
Multiplexes were developed using an excess of streptavidin-
phycoerythrin  solution,  which  was  thoroughly  mixed  into
each multiplex and incubated for 1 h at room temperature. The
volume of each multiplexed reaction was reduced by vacuum
filtration and the volume increased by dilution into matrix
buffer for analysis. Analysis was performed in a Luminex 100
instrument and the resulting data stream was interpreted using
proprietary data analysis software (developed at Rules-Based
Medicine and licensed to Qiagen Instruments, Valencia, CA).
For  each  multiplex,  both  calibrators  and  controls  were
included on each microtiter plate. Eight-point calibrators were
run in the first and last column of each plate and three-level
controls  were  included  in  duplicate.  Testing  results  were
determined first for the high, medium, and low controls for
each multiplex to ensure proper assay performance. Unknown
values for each of the analytes localized in a specific multiplex
were determined using four and five parameters and weighted
and non-weighted curve fitting algorithms included in the data
analysis package.
Analysis:  The  value  for  each  analyte  was  obtained  as  a
concentration (e.g., mg/ml). The values of eight samples (or
less if an analyte could not be analyzed in all samples because
of insufficient quantity of the sample) were averaged and
compared to the sensitivity of the system. An analyte was
considered “detectable” if the levels exceeded the minimal
detectable  levels.  The  standard  deviation  for  the  detected
analytes  was  calculated  using  an  Excel®  (Microsoft,
Redmond, VA) spreadsheet. The pre-treatment levels were
compared with previously published data on normal aqueous
samples that were obtained from patients undergoing cataract
surgery  without  any  other  ocular  pathology.  The  data  on
normal  samples  was  previously  published  [5].  Since  the
microbead assay is highly reproducible [6], it is therefore
possible to compare values from different assays. Thus, the
previously published results were used as a control for pre-
and post-treatment samples. The pre-treatment samples were
also compared with the post-treatment samples to elucidate
the  effect  of  intravitreal  bevacizumab  injections.  Further,
cluster analysis was performed on the analytes detected in all
three conditions (normal, pre-treatment, and post-treatment).
For cluster analysis, the gene ID for the analytes was identified
and  log  values  of  the  data  were  used  to  import  them  to
Cluster and Treeview software. Red indicates upregulated
analytes and green indicates low expression. The purpose of
cluster analysis was to provide an easily appreciable global
view of changes in analyte values in normal, pre-treatment
and post-treatment samples.
Statistical  analysis:  Tukey’s  post-hoc  test  was  used  to
determine the significant differences in two groups of analytes
(pre-treated versus normal and post-treated versus normal).
Unsupervised  hierarchical  average-link  clustering  using
Cluster and Treeview (Eisen Laboratory, Stanford University,
Palo Alto, CA) was done to find patterns in analyte expression
levels.
RESULTS
A total of 90 analytes represented on MAP analytes were
analyzed. Of the 90 analytes, 43 were detected in pre- and
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we obtained control values (values from aqueous obtained
from  non-pathological  eyes)  for  41.  Two  analytes
(interleukin-7 [IL-7] and inter-cellular adhesion molecule-1
[ICAM-1]) were detected in pre- and post-treatment samples,
but not in control samples. A list of analytes detected in all the
samples is provided in Table 1. These 41 analytes were further
analyzed.  Further  analysis  revealed  that  of  41  analytes
common to the control and pre-treatment samples, 10 were
down-regulated  in  pre-treatment  samples  and  31  were
upregulated (Figure 1). Of the 43 analytes common to pre- and
post-treatment  samples,  seven  analytes  were  upregulated
compared to the pre-treatment samples and the other 36 were
down-regulated,  suggesting  a  trend  toward  normalization
(Figure 2). To further confirm this observation, the 41 analytes
that were common to pre- and post-treatment samples and
were  also  reported  in  normal  samples  were  individually
compared to see if the changes observed in the pre-treatment
samples (aqueous from diseased eyes) as compared to control
samples (normal values) were reversed after bevacizumab
injection in post-treatment samples. Toward this goal, we
identified 24 analytes that demonstrated a 1.5 fold or more
difference (upregulation or down-regulation) in pre-treatment
samples  as  compared  to  the  normal  samples;  then  we
compared this change to the post-treatment samples. This cut-
off limit was chosen to eliminate analytes that might have
shown some differences merely by chance when compared to
controls.  Values  between  a  1.5  and  threefold  change  are
generally used in gene expression studies [7-9]. Although
these studies relate to microarray analysis, it is reasonable to
employ similar cut-off limits to other studies such as this. The
upregulated  analytes  included  IL-6,  IL-8,  erythropoietin,
basic  fibroblast  growth  factor  (bFGF),  CD40,  C-reactive
protein,  fibronigen,  VEGF,  and  tissue  inhibitor  of
metalloproteinase  (TIMP-1).  The  down-regulated  analytes
included  glutathione  s-transferase,  complement  3,  and
insulin-like growth factor (IGF-1). In all the 21 upregulated
pre-treated analytes, there was a trend toward normalization
of the values (Figure 3). All three down-regulated pre-treated
analytes did not show any response to treatment.
Further  cluster  analysis  confirmed  that  bevacizumab
treatment normalized the expression level of detected analytes
toward normal values, as published earlier [5] (Figure 4).
DISCUSSION
Multi-analyte profiles are a fully validated technique [10]
based on Luminex technology. This assay performs up to 100
multiplexed, microsphere-based assays in a single reaction
vessel  by  combining  optical  classification  schemes,
biochemical assays, flow cytometry, and advanced digital
signal processing hardware and software. Research Based
Medicine’s MAPs represent the number of markers relevant
to  neovascular  pathology  such  as  hormones,  cytokines/
chemokines, acute phase reactants, clotting proteins, growth
factors,  tissue  modeling  factors,  and  other  typical  plasma
proteins [11]. Using MAPs to measure a broad spectrum of
biomarkers,  a  comprehensive  analysis  of  intraocular
physiologic status can be obtained [5]. We hypothesized that
such  an  analysis  could  be  useful  in  understanding  the
pathobiology  of  a  disease,  assessing  its  progression,  or
assessing the response to a treatment. We provided the proof
of  principle  by  comparing  two  diabetic  samples  and
demonstrating relevant differences in aqueous profiles [5]. In
the current study, we used this technique to study how an
aqueous profile consisting of 90 analytes represented on the
MAP differed in pathological samples compared to previously
published values from non-neovascular (normal) samples. We
further  analyzed  post-treatment  samples  from  the  same
patients to see whether the aqueous humor profile normalized
after intravitreal injection. Using the same multiplex in our
previous study, we provided baseline values of 52 analytes.
Since microbead assays are highly reproducible, it permits
inter-experiment comparison [6]. Therefore, we were able to
compare  pre-  and  post-treatment  values  with  previously
published normal values. Many of the detected analytes such
as IL-6, IL-8, granulocyte colony-stimulating factor (G-CSF),
fibrinogen,  VEGF,  matrix  metalloproteinase  3  (MMP3),
erythropoietin,  bFGF,  TIMP-1,  CD40,  C  reactive  protein,
endothelin, and glutathione S-transferase are implicated in
ocular  pathologies  and  therefore  their  measurement  could
provide useful information [12-15]. The changes observed in
pathological samples were consistent with the neovascular
and permeability-related pathophysiology. Analytes relevant
to  neovascular  pathology  that  showed  increased  levels
included IL-6, C reactive protein, fibrinogen, IL-8, VEGF,
MMP-3, erythropoietin, CD40, bFGF, and TIMP-1 [16,17].
Equally  relevant  for  neovascular  pathophysiology  were
glutathione  S  and  IGF-1,  which  were  down-regulated  in
aqueous samples [18,19]. It may be noted that the standard
deviations for many analytes in this study were relatively
large. This reflects the wide range of analyte values among
different patients. We did not make any effort to control the
recruitment  of  patients  based  on  the  level  of  analyte.
Therefore, the level of analytes present in the aqueous varies
widely between the individuals (range was large), reflecting
individual variation, disease process, and the stages of disease.
Most significantly, this study demonstrated that the effect
of  anti-VEGF  therapy  on  the  in  oculo  pathophysiological
environment extended beyond neutralization of VEGF [20].
We identified 24 analytes that were distinctly changed (1.5
fold or more) in the aqueous from the pathological samples as
compared to normal values. Analysis of these analytes in the
same patients after the bevacizumab injection demonstrated
that  all  analytes  upregulated  in  pre-treatment  tended  to
normalize after the treatment. Many of these analytes are not
directly related to the function of VEGF. These results provide
strong  and  unequivocal  evidence  that  the  bevacizumab
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beyond what could be expected by neutralization of VEGF
alone. These results were confirmed by a global view of the
changes  provided  by  the  cluster  analysis.  The  purpose  of
cluster analysis in this study was not to group analytes, but
rather to use the color coding that expresses the analyte levels
to show how all the analytes in Table 1 changed in three
different conditions. It is apparent from looking at Figure 4
that bevacizumab treatment had a wide-ranging impact on the
aqueous profile toward normalization. It is possible that some
of the changes noted may be the result of the regression of the
disease  process  (indirect  effect  of  the  treatment)  or  the
reestablishment of the blood-retinal barrier rather than the
direct effect of the bevacizumab injection.
Clinical  observations  suggest  that  the  bevacizumab
treatment changes the clinical course of neovascularization in
a manner that cannot be entirely explained by the VEGF
neutralizing effect of bevacizumab. For instance, intracameral
injection  of  bevacizumab  for  iris  neovascularization  lasts
longer  than  bevacizumab  availability  in  the  aqueous  [20]
TABLE 1. LIST OF ANALYTES DETECTED IN PATHOLOGICAL AQUEOUS SAMPLES (PRE-TREATMENT) AND AFTER INTRAVITREAL BEVACIZUMAB INJECTION (POST-
TREATMENT).
Analyte Units Pre-treatment
mean
Pre-treatment
SD
Post-treatment
mean
Post-
treatment SD
Alpha-1 Antitrypsin mg/ml 0.0022 0.0012 0.0025 0.0011
Alpha-Fetoprotein ng/ml 0.2626 0.0569 0.2790 0.0636
Apolipoprotein A1 mg/ml 0.0007 0.0008 0.0004 0.0004
Apolipoprotein CIII ug/ml 0.0424 0.0188 0.0259 0.0032
Apolipoprotein H ug/ml 0.8176 0.7303 0.6400 0.5762
Beta-2 Microglobulin ug/ml 0.4088 0.3180 0.3026 0.1879
C Reactive Protein ug/ml 0.1114 0.1521 0.0477 0.0514
Cancer Antigen 125 U/ml 1.7363 0.4314 1.7225 0.3476
Cancer Antigen 19–9 U/ml 0.2952 0.1282 0.2042 0.1177
CD40 ng/ml 0.0676 0.0598 0.0510 0.0334
Complement 3 mg/ml 0.0013 0.0007 0.0014 0.0010
Endothelin-1 pg/ml 5.4863 1.7494 5.2375 0.6159
Eotaxin pg/ml 17.7750 4.6849 13.5813 5.1661
Erythropoietin pg/ml 120.5875 125.032 111.6125 130.0555
FGF basic pg/ml 52.2375 18.8596 30.8900 20.8668
Fibrinogen mg/ml 0.0011 0.0018 0.0005 0.0005
G-CSF pg/ml 17.2825 31.2826 3.6748 2.8391
Glutathione S-Transferase ng/ml 0.1406 0.0164 0.1544 0.0154
Haptoglobin mg/ml 0.0005 0.0005 0.0004 0.0005
IgA mg/ml 0.0014 0.0011 0.0015 0.0016
IGF-1 ng/ml 1.4248 0.7489 1.4285 0.8083
IgM mg/ml 0.0013 0.0012 0.0009 0.0008
IL-6 pg/ml 120.2543 293.001 15.2016 19.9646
IL-8 pg/ml 22.9475 30.8635 14.9900 9.5664
Leptin ng/ml 0.3806 0.5658 0.2131 0.3830
MCP-1 pg/ml 638.0000 618.982 438.3750 263.5244
MIP-1alpha pg/ml 10.3625 3.0867 9.4175 2.4535
MIP-1beta pg/ml 24.8738 20.2587 21.7988 14.5772
MMP-3 ng/ml 0.6362 1.2937 0.6159 0.4960
PAPP-A U/ml 0.0526 0.0558 0.0432 0.0306
Prostate Specific Antigen, Free ng/ml 0.0169 0.0066 0.0092
Prostatic Acid Phosphatase ng/ml 0.0260 0.0273 0.0095 0.0054
Serum Amyloid P ug/ml 0.0287 0.0303 0.0134 0.0081
SGOT ug/ml 1.8149 0.6531 1.3488 0.3111
SHBG nmol/l 0.5133 0.3151 0.2250 0.0866
Stem Cell Factor pg/ml 19.9938 6.1891 19.4375 2.5757
Thyroid Stimulating Hormone U/ml 0.0293 0.0252 0.0188 0.0107
Thyroxine Binding Globulin ug/ml 0.6370 0.6607 0.3876 0.3822
TIMP-1 ng/ml 30.9825 29.6818 22.3825 14.6893
Tissue Factor ng/ml 0.3724 0.0820 0.3631 0.0698
VEGF pg/ml 679.6250 299.134 484.1250 346.3955
ICAM-1 ng/ml 0.7900 0.7117 0.6971 0.4189
IL-7 pg/ml 11.4175 1.5109 12.3125 1.1753
        This shows the mean values and standard deviation (SD) of 41 analytes that were detectable and for which control values were
        available. SD=Standard Deviation.
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2178Figure 1. Differences in normal and pathological samples. The figure shows the fold change in the analyte profile in the aqueous humor of
patients with VEGF-related pathologies (pre-treatment samples) as compared to known normal values. The 41 analytes that were detected in
the aqueous humor of the eyes with VEGF-related pathology were compared with the normal values previously published. The changes are
presented as fold change. Ten analytes were down-regulated and 31 were upregulated.
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2179Figure 2. Changes after treatment compared to pretreatment values. The figure shows fold change in the analyte profile in the aqueous humor
of patients with VEGF-related pathologies (pre-treatment samples) as compared to the aqueous profile of treated patients (post-treatment).
Forty-three analytes were common in pre- and post-treatment samples; out of these, seven analytes were upregulated and the other 36 were
down-regulated, suggesting a trend toward normalization.
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2180Figure 3. Trend toward normalization of pathological analyte profile after bevacizumab treatment. This figure shows a comparison of 24
analytes that showed a 1.5 fold or more change in the aqueous of eyes with VEGF-related pathology as compared to normal values. The effect
of treatment on the analyte profile was followed by analyzing the samples from the same patients after treatment. The figure shows that all
analytes upregulated in pre-treatment samples showed a trend toward normalization. Two groups of analytes (pre-treated versus normal and
post-treated versus normal) were compared for each analyte using the Tukey’s post-hoc comparison test. Stars show significant differences
(p<0.05) between pre-treated versus normal.
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2181Figure 4. Cluster analysis to provide a global view of changes in all 41 analytes in pre- and post-treatment samples as compared to normal.
Log values were used for importing data to Cluster and Treeview software. Red indicates upregulated analytes; green indicates low expressed
analytes. The left column shows control values, the middle column shows post-treatment values, and the right column shows pre-treatment
values.
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2182considering aqueous is produced at a rate of 2–3 µl/min and
the  volume  of  anterior  chamber  is  approximately  250  µl.
Similarly, the effect of intravitreal injection of bevacizumab
lasts  for  months,  longer  than  the  bioavailability  of
bevacizumab [21,22]. In addition, bevacizumab treatment not
only  arrests  the  progression  of  neovascularization,  but  in
many cases reverses it, which again cannot be explained by
the  effect  of  VEGF  on  endothelial  cell  proliferation  and
migration alone [20]. Our results provide clues that the trend
toward the global normalization of the ocular physiologic
environment  by  bevacizumab  injection  could  alter  the
pathophysiology of the disease process and thus potentially
provide an explanation for these observations.
One of the limitations of the study was that the MAPs we
used were not specifically designed for ocular pathologies.
However, based on this technology, ocular pathology-specific
MAPs  could  be  designed.  These  results  suggest  that
expression profiling of the aqueous by specifically designed
MAPs  could  provide  valuable  insight  into  the  disease
processes and treatment responses using a systems approach.
Such an approach could facilitate deduction of the complex
networks that underlie biologic processes and characterization
of their state when perturbed by disease [23]. This approach
would aid understanding of the various aspects of diseases,
including  their  classification,  pathobiology,  treatment
responses, and prognoses [24] as well as open the door for
personalized,  tailored  strategies  for  ocular  diseases  at  all
levels of management.
ACKNOWLEDGMENTS
This study was partly funded by the Dean’s Grant Support,
University of Florida, Jacksonville, FL to R.K.S., other funds
were provided from departmental resources.
REFERENCES
1. Bhattacharya R, Kwon J, Li X, Wang E, Patra S, Bida JP, Bajzer
Z,  Claesson-Welsh  L,  Mukhopadhyay  D.  Distinct  role  of
PLCbeta3  in  VEGF-mediated  directional  migration  and
vascular sprouting. J Cell Sci 2009; 122:1025-34. [PMID:
19295129]
2. Hervé  MA,  Buteau-Lozano  H,  Mourah  S,  Calvo  F,  Perrot-
Applanat  M.  VEGF189  stimulates  endothelial  cells
proliferation  and  migration  in  vitro  and  up-regulates  the
expression  of  Flk-1/KDR  mRNA.  Exp  Cell  Res  2005;
309:24-31. [PMID: 15996656]
3. Loscalzo  J,  Kohane  I,  Barabasi  AL.  Human  disease
classification  in  the  postgenomic  era:  a  complex  systems
approach  to  human  pathobiology.  Mol  Syst  Biol  2007;
3:124. [PMID: 17625512]
4. Martin  M,  Reidhaar-Olson  JF,  Rondinone  CM.  Genetic
association  meets  RNA  interference:  large-scale  genomic
screens for causation and mechanism of complex diseases.
Pharmacogenomics 2007; 8:455-64. [PMID: 17465709]
5. Sharma  RK,  Rogojina  AT,  Chalam  KV.  Multiplex
immunoassay analysis of biomarkers in clinically accessible
quantities  of  human  aqueous  humor.  Mol  Vis  2009;
15:60-9. [PMID: 19145248]
6. Curnow SJ, Falciani F, Durrani OM, Cheung CM, Ross EJ,
Wloka  K,  Rauz  S,  Wallace  GR,  Salmon  M,  Murray  PI.
Multiplex  bead  immunoassay  analysis  of  aqueous  humor
reveals  distinct  cytokine  profiles  in  uveitis.  Invest
Ophthalmol Vis Sci 2005; 46:4251-9. [PMID: 16249505]
7. Yuan L, Hillman JD, Progulske-Fox A. Microarray analysis of
quorum-sensing-regulated  genes  in  Porphyromonas
gingivalis.  Infect  Immun  2005;  73:4146-54.  [PMID:
15972504]
8. Schachter PP, Ayesh S, Matouk I, Schneider T, Czerniak A,
Hochberg  A.  Differential  expression  of  kinase  genes  in
primary hyperparathyroidism: adenoma versus normal and
hyperplastic parathyroid tissue. Arch Pathol Lab Med 2007;
131:126-30. [PMID: 17227113]
9. Klener  P,  Szynal  M,  Cleuter  Y,  Merimi  M,  Duvillier  H,
Lallemand F, Bagnis C, Griebel P, Sotiriou C, Burny A,
Martiat P. Van den BA. Insights into gene expression changes
impacting  B-cell  transformation:  cross-species  microarray
analysis of bovine leukemia virus tax-responsive genes in
ovine B cells. J Virol 2006; 80:1922-38. [PMID: 16439548]
10. Heuer JG, Zhang T, Zhao J, Ding C, Cramer M, Justen KL,
Vonderfecht  SL,  Na  S.  Adoptive  transfer  of  in  vitro-
stimulated CD4+CD25+ regulatory T cells increases bacterial
clearance and improves survival in polymicrobial sepsis. J
Immunol 2005; 174:7141-6. [PMID: 15905557]
11. Gurbel PA, Kreutz RP, Bliden KP, Dichiara J, Tantry US.
Biomarker  analysis  by  fluorokine  multianalyte  profiling
distinguishes  patients  requiring  intervention  from  patients
with long-term quiescent coronary artery disease: a potential
approach to identify atherosclerotic disease progression. Am
Heart J 2008; 155:56-61. [PMID: 18082490]
12. Symeonidis  C,  Diza  E,  Papakonstantinou  E,  Souliou  E,
Dimitrakos SA, Karakiulakis G. Correlation of the extent and
duration  of  rhegmatogenous  retinal  detachment  with  the
expression  of  matrix  metalloproteinases  in  the  vitreous.
Retina 2007; 27:1279-85. [PMID: 18046238]
13. Laine M, Jarva H, Seitsonen S, Haapasalo K, Lehtinen MJ,
Lindeman N, Anderson DH, Johnson PT, Jarvela I, Jokiranta
TS, Hageman GS, Immonen I, Meri S. Y402H polymorphism
of complement factor H affects binding affinity to C-reactive
protein. J Immunol 2007; 178:3831-6. [PMID: 17339482]
14. Wang  X,  Baldridge  WH,  Chauhan  BC.  Acute  endothelin-1
application induces reversible fast axonal transport blockade
in adult rat optic nerve. Invest Ophthalmol Vis Sci 2008;
49:961-7. [PMID: 18326719]
15. Witmer AN, Vrensen GF, Van Noorden CJ, Schlingemann RO.
Vascular endothelial growth factors and angiogenesis in eye
disease.  Prog  Retin  Eye  Res  2003;  22:1-29.  [PMID:
12597922]
16. Simó  R,  Carrasco  E,  Garcia-Ramirez  M,  Hernandez  C.
Angiogenic  and  antiangiogenic  factors  in  proliferative
diabetic  retinopathy.  Curr  Diabetes  Rev  2006;  2:71-98.
[PMID: 18220619]
17. Bulcão C, Ferreira SR, Giuffrida FM, Ribeiro-Filho FF. The
new adipose tissue and adipocytokines. Curr Diabetes Rev
2006; 2:19-28. [PMID: 18220614]
18. Kim  SK,  Novak  RF.  The  role  of  intracellular  signaling  in
insulin-mediated  regulation  of  drug  metabolizing  enzyme
gene  and  protein  expression.  Pharmacol  Ther  2007;
113:88-120. [PMID: 17097148]
Molecular Vision 2010; 16:2175-2184 <http://www.molvis.org/molvis/v16/a233> © 2010 Molecular Vision
218319. Rabinovitch A. An update on cytokines in the pathogenesis of
insulin-dependent  diabetes  mellitus.  Diabetes  Metab  Rev
1998; 14:129-51. [PMID: 9679667]
20. Grover  S,  Gupta  S,  Sharma  R,  Brar  VS,  Chalam  KV.
Intracameral  bevacizumab  effectively  reduces  aqueous
VEGF  levels  in  neovascular  glaucoma.  Br  J  Ophthalmol
2009; 93:273-4. [PMID: 9679667]
21. Krohne  TU,  Eter  N,  Holz  FG,  Meyer  CH.  Intraocular
pharmacokinetics of bevacizumab after a single intravitreal
injection in humans. Am J Ophthalmol 2008; 146:508-12.
[PMID: 18635152]
22. Miyake T, Sawada O, Kakinoki M, Sawada T, Kawamura H,
Ogasawara K, Ohji M. Pharmacokinetics of bevacizumab and
its  effect  on  vascular  endothelial  growth  factor  after
intravitreal injection of bevacizumab in macaque eyes. Invest
Ophthalmol Vis Sci 2010; 51:1606-8. [PMID: 19875666]
23. Ergün A, Lawrence CA, Kohanski MA, Brennan TA, Collins
JJ. A network biology approach to prostate cancer. Mol Syst
Biol 2007; 3:82. [PMID: 17299418]
24. Knickerbocker  T,  Chen  JR,  Thadhani  R,  MacBeath  G.  An
integrated approach to prognosis using protein microarrays
and  nonparametric  methods.  Mol  Syst  Biol  2007;  3:123.
[PMID: 17593911]
Molecular Vision 2010; 16:2175-2184 <http://www.molvis.org/molvis/v16/a233> © 2010 Molecular Vision
The print version of this article was created on 22 October 2010. This reflects all typographical corrections and errata to the
article through that date. Details of any changes may be found in the online version of the article.
2184